TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: glycosylated haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fissure pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cleveland Clinic Incontinence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LP success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MS Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean decrease in mFGS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft-versus-host disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: reduction of retinal hemorrhage, fluid, and lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in the number of ranibizumab injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of stroke, death or procedural myocardial infarction (MI) within 120 days
Endpoint domain: Mortality/survival
Primary endpoint: Fatal or disabling stroke within 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Stroke of any severity
Endpoint domain: Mortality/survival
Primary endpoint: Social acceptance of IPV among women
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Past year experience of physical IPV among women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past year sexual concurrency by men
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high-quality embryos rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Ca2+ concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in emergency department visits for asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from sore throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from sickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perinatal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physician behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of individuals with a decrease of >30% in plasma NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence rates at week 26
Endpoint domain: Mortality/survival
Primary endpoint: Weight gain at week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alterations in spontaneous EEG variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean cord separation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderation of drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operator radiation dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient radiation dose increase
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom scores decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs scores decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevated intraocular pressure
Endpoint domain: Adverse events/effects
Primary endpoint: Laxative use (as an indicator of constipation severity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum albumin, prealbumin and protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of binary in-segment restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of target-lesion revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma arecoline level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BOP around NDIs and RDIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of the mean 2‐h OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hydrocele occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Pain evaluation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of office visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Microbial composition change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of EE and drospirenone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC values and C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of L-5-methyl-THF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete the test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant preference for response method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Freedom from MRI scan-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of progressing stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: incidence of post-herpetic neuralgia
Endpoint domain: Adverse events/effects
Primary endpoint: time for pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood glucose levels at 1h of the OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood glucose levels at 2h of the OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of acute posttraumatic bacterial endophthalmitis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of inductions at 42 weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase in LDL buoyancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in hepatic lipase (HL) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in coronary stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evolution of body mass index (BMI) after SG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total time to complete the nine 20-m sprints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient bradycardia (≥20% drop in HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic BP drop compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adoption of safety practices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness of fumaric acid derivatives in treating psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of fumaric acid derivatives (adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of missed appointments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visfatin concentrations in serum and GCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Healing rate of lymphocytic gastritis after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Antibody titre decrease of 25% at M6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous intrauterine pregnancy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Tubal patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: 20‐Item Sino‐Nasal Outcome Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasal endoscopic examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥ 1 log10 IU/mL decline in HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade ≥ 3 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: throat symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change ratio of serum total IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HARS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute aerobic capacity (V˙O2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal workload (Wattmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of ACB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 6MWT distance walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of QHBS parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission rate at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: tolerance of nutritional supplementation
Endpoint domain: Adverse events/effects
Primary endpoint: weight and body mass index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of blood products
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postprocedure bleeding complications
Endpoint domain: Adverse events/effects
Primary endpoint: emotional state and regulation ability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: behavioural and self-management style
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Survival with an intact valve
Endpoint domain: Mortality/survival
Primary endpoint: total prevalence and survival rates
Endpoint domain: Mortality/survival
Primary endpoint: total radiation injury occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Displacement of DLTs during lateral positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of significant displacement (> 10 mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ability to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Prevalence of depression in T2DP
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: TGs decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Left atrial (LA) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death or heart failure (HF)
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft survival at 36 months
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in mMASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: cardiometabolic health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: self-reported physical quality of life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: residual US size of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in recognition of risky dog situations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WBNAA deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Global atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GM atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hair reduction greater than 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percent of days with no asthma symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy for identifying appropriate portion sizes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Consumption of sugar-sweetened beverages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gains in oral language skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: persistent or recurrent primary hyperparathyroidism (pHPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak systolic velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial acceleration during isovolumic contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma level of amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stigmatisation of mental health conditions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trivialisation of mental health conditions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proinsulin levels above 5 pmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: C-peptide levels above 0.2 nmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: swollen and tender joint count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to resolution of arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Administration Errors (MAOEs)
Endpoint domain: Adverse events/effects
Primary endpoint: biochemical recurrence-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Collecting near point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative score of eye symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentration of sICAM‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tissue concentration of sICAM‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative intra-abdominal abscess rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Voice onset time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of short phonated intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kinematic shoulder and elbow motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of neutropenic fever
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of patients with clinically relevant Global Health Status deterioration
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: bone structural parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: pain responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain-free period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for supplementary analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: dermal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in clinical grading of photodamage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypotensive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time consumption during procedure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Final IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Final IL-8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in urine Dpd levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maintenance of serum NTx levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in serum BAP and OC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Deaths prevented
Endpoint domain: Mortality/survival
Primary endpoint: Hospitalizations prevented
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: adalimumab concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MBL (Marginal Bone Level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance (IADL)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sleep efficiency (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Remission at week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response at week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Termination of the trial prior to week 10
Endpoint domain: Adverse events/effects
Primary endpoint: Overall tolerance of EGD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall discomfort during EGD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturia count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MPA after ADP stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum TH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean time to extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS for pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: median operating time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Objective sleep efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: average daily fruit consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: average daily water intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bacterial eradication rate of sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Turnaround time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decrease in serum androgen markers (A, total T, SHBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decrease in DHEAS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of coughing during intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of movement during intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Ventilation dependency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of CIPNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: postoperative recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: menstrual pain improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: chronic pelvic pain improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Optimal surgical space conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Negative Predictive Value (NPV) for sIgE ≥0.35 kU(A)/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Predictive Value (PPV) for sIgE ≥0.35 kU(A)/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with echographic evidence of fatty liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes